Julia Harwardt
Hat mitgewirkt an:
-
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
-
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
-
Aktivierung natürlicher Killerzellen zur Behandlung von Tumorerkrankungen
-
TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome